Advanced Development and Validation of Emerging Technologies for Cancer-Relevant Biospecimen Science (R33)

Post Date

December 8th 2015

Application Due Date

September 26th 2016

Funding Opportunity Number

RFA-CA-16-004

CFDA Number(s)

93.394

Funding Instrument Type(s)

Grant

Funding Activity Categories

Education
Health

Number of Awards

2

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Funding

• Estimated Total Funding:

  $800000

• Award Range:

  $None - $300000

Grant Description

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the advanced development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes technologies that address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and storage of cancer-relevant biospecimens. This FOA solicits R33 applications where proof-of-principle for the emerging technology or methodology has been provided with supportive preliminary data demonstrating a novel capability for maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or cancer health disparities. Projects proposing to use established technologies where the novelty resides in the biological or clinical question being pursued are not appropriate for this FOA and will not be reviewed.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-16-004.html